Tyme Technologies, Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology indications. It is developing SM-88, a combination therapy in Phase II development for prostate cancer. The company has a co-development agreement with the University of California San Francisco to evaluate SM-88 therapy in prostate cancer. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TYME
CUSIPN/A
Phone646-205-1603
Debt
Debt-to-Equity RatioN/A
Current Ratio6.83
Quick Ratio6.83
Price-To-Earnings
Trailing P/E Ratio-19.72
Forward P/E Ratio-15.43
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.27 per share
Price / Book13.15
Profitability
EPS (Most Recent Fiscal Year)($0.18)
Net Income$-18,960,000.00
Net MarginsN/A
Return on Equity-153.04%
Return on Assets-118.35%
Miscellaneous
EmployeesN/A
Outstanding Shares101,230,000
Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions
What is Tyme Technologies' stock symbol?
Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."
What price target have analysts set for TYME?
3 analysts have issued 12 month price targets for Tyme Technologies' shares. Their forecasts range from $7.00 to $9.50. On average, they anticipate Tyme Technologies' share price to reach $8.25 in the next year. View Analyst Ratings for Tyme Technologies.
What are Wall Street analysts saying about Tyme Technologies stock?
Here are some recent quotes from research analysts about Tyme Technologies stock:
- 1. Canaccord Genuity analysts commented, "We continue to view SM-88’s ability to generate responses across ~15 solid and liquid tumor types and with durable effect in advanced cancer patients progressing on available therapies as intriguing and reiterate our BUY rating." (6/15/2018)
- 2. According to Zacks Investment Research, "Tyme Technologies, Inc. is a pharmaceutical company. The company is focused on creating medicines which specialize in the body's immune system to treat diseases. Tyme Technologies, Inc. is headquartered in New York. " (4/12/2018)
Who are some of Tyme Technologies' key competitors?
Some companies that are related to Tyme Technologies include Radius Health (RDUS), Uniqure (QURE), Lexicon Pharmaceuticals (LXRX), ImmunoGen (IMGN), Impax Laboratories (IPXL), IMMURON Ltd/S (IMRN), Theravance Biopharma (TBPH), Apellis Pharmaceuticals (APLS), Athenex (ATNX), Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB), Alder Biopharmaceuticals (ALDR), Retrophin (RTRX), Revance Therapeutics (RVNC) and Intra-Cellular Therapies (ITCI).
Who are Tyme Technologies' key executives?
Tyme Technologies' management team includes the folowing people:
- Mr. Steven E. Hoffman, CEO & Director (Age 55)
- Mr. Michael S. Demurjian, Chief Operating Officer and Director (Age 51)
- Mr. Ben R. Taylor, Pres & CFO (Age 41)
- Dr. Jonathan M. Eckard, Chief Scientific Affairs Officer
- Dr. Giuseppe Del Priore M.D., MPH, Chief Medical Officer (Age 56)
Has Tyme Technologies been receiving favorable news coverage?
Media headlines about TYME stock have trended positive on Wednesday, Accern Sentiment reports. Accern identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Tyme Technologies earned a daily sentiment score of 0.43 on Accern's scale. They also gave press coverage about the company an impact score of 48.26 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are Tyme Technologies' major shareholders?
Tyme Technologies' stock is owned by a number of of institutional and retail investors. Top institutional investors include Millennium Management LLC (1.55%), Farallon Capital Management LLC (1.43%) and Family Management Corp (0.14%). Company insiders that own Tyme Technologies stock include Michael Demurjian and Steve Hoffman. View Institutional Ownership Trends for Tyme Technologies.
Which major investors are buying Tyme Technologies stock?
How do I buy shares of Tyme Technologies?
Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tyme Technologies' stock price today?
One share of TYME stock can currently be purchased for approximately $3.55.
How big of a company is Tyme Technologies?
Tyme Technologies has a market capitalization of $349.23 million. The company earns $-18,960,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis.
How can I contact Tyme Technologies?
Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 646-205-1603 or via email at [email protected]
MarketBeat Community Rating for Tyme Technologies (TYME)
MarketBeat's community ratings are surveys of what our community members think about Tyme Technologies and other stocks. Vote "Outperform" if you believe TYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TYME will underperform the S&P 500 over the long term. You may vote once every thirty days.
